Posted 11/2/2023, 3:38:00 PM
Mounjaro Sales Surge Over 650% to $1.4B, Fueling Lilly's Strong Q3 Earnings Beat
- Eli Lilly beats Q3 forecasts as diabetes drug Mounjaro sales surge 652% to $1.41B
- Mounjaro growth fuels 36% revenue increase to $9.5B, though other drugs lag expectations
- Lilly cuts 2022 EPS outlook on tax charges but retains $33.4B-$33.9B sales view
- Breast cancer med Verzenio sales jump 68% to $1.04B, topping $1B estimate
- Lilly stock surges over 5% as Mounjaro growth sparks bullish analyst reactions
